A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

NCT02087423 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

446

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: MEDI4736

Sponsor

AstraZeneca